caffeine has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parra-Guillen, ZP | 1 |
| Berger, PB | 1 |
| Haschke, M | 1 |
| Donzelli, M | 1 |
| Winogradova, D | 1 |
| Pfister, B | 1 |
| Früh, M | 1 |
| Gillessen, S | 1 |
| Krähenbühl, S | 1 |
| Kloft, C | 1 |
| Joerger, M | 1 |
| Roberson, RS | 1 |
| Kussick, SJ | 1 |
| Vallieres, E | 1 |
| Chen, SY | 1 |
| Wu, DY | 1 |
| Tsai, CM | 1 |
| Perng, RP | 1 |
| Chen, MH | 1 |
| Jan, YH | 1 |
| Hung, MC | 1 |
| Ku, TY | 1 |
| Chang, KT | 1 |
| Ogasawara, H | 1 |
| Nishio, K | 1 |
| Ishida, T | 1 |
| Arioka, H | 1 |
| Fukuoka, K | 1 |
| Saijo, N | 1 |
| Roots, I | 1 |
| Drakoulis, N | 1 |
| Ploch, M | 1 |
| Heinemeyer, G | 1 |
| Loddenkemper, R | 1 |
| Minks, T | 1 |
| Nitz, M | 1 |
| Otte, F | 1 |
| Koch, M | 1 |
1 trial available for caffeine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Topics: Aged; Antineoplastic Agents; Caffeine; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Cytoc | 2017 |
4 other studies available for caffeine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Caffeine; Camptothecin; Carboplatin; Carcinoma, Non- | 2005 |
Greater enhancement of chemosensitivity by caffeine in high-p185neu-expressing human non-small-cell lung cancer cell lines.
Topics: Biomarkers, Tumor; Caffeine; Carcinoma, Non-Small-Cell Lung; Drug Synergism; ErbB Receptors; Gene Ex | 1994 |
In vitro enhancement of antitumor activity of a water-soluble duocarmycin derivative, KW-2189, by caffeine-mediated DNA-repair inhibition in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Caffeine; Carcinoma, Non-Small-Cell Lung; DNA Damage | 1997 |
Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Topics: ABO Blood-Group System; Acetylation; Acetyltransferases; Arylamine N-Acetyltransferase; Caffeine; Ca | 1988 |